Clinical Trial Update: Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study evaluating safety, reactogenicity and immunogenicity of Ad26- and MVA-vectored vaccine components for HPV16/HPV18 cervical infections in otherwi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Papillomavirus Infections

Drugs mentioned

• Ad26-vectored HPV vaccine component (Adenovirus serotype 26 vector)
• MVA-vectored HPV vaccine component (Modified Vaccinia Ankara vector)

Snippet

Sponsor: Janssen Vaccines & Prevention B.V. | Conditions: Human Papillomavirus Infections | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-11-09